中泰证券医药首席祝嘉琦：2026医药投资把握“两极”机遇，创新与反转双线布局

Core Insights - The 2025 Analyst Conference highlighted the potential for a bull market in A-shares, attracting global capital inflows [1][3] - The event gathered over 300 industry experts to discuss future opportunities in the Chinese capital market [1][3] Investment Strategy - The pharmaceutical sector is expected to exhibit a "dual strength" characteristic in 2025, with leading companies maintaining robust performance while small-cap firms with technological breakthroughs also showing promise [1][3] - Analysts recommend a "core leaders and growth enhancers" strategy, focusing on strong companies while also investing in high-growth small-cap stocks to achieve a balance of stability and flexibility [1][3] Focus Areas for 2026 - Two main investment themes were emphasized: 1. Innovation-Driven Theme: Innovative drugs and their supply chains are seen as key long-term growth drivers, closely linked to market risk appetite [2][5] 2. Turnaround Theme: Certain sub-sectors like medical devices, traditional Chinese medicine, and consumer healthcare are showing signs of recovery, making them suitable for defensive positioning during market fluctuations [2][5] Market Dynamics - The valuation of innovative drugs is highly correlated with market sentiment towards technology stocks, necessitating a dynamic investment perspective [2][5] - The internal rotation within the pharmaceutical sector is expected to balance between "growth (innovative drugs)" and "safety (turnaround)" depending on market conditions [2][5]